Duke University

LG ELECTRONICS ANNOUNCES THIRD SEASON OF MENTAL HEALTH AWARENESS PODCAST 'TRANSPARENT CONVERSATIONS'

Retrieved on: 
목요일, 5월 9, 2024
Message, Organization, University, LG Electronics, National Collegiate Athletic Association, System, Arizona State University, NFL, Season, Rook, Lacrosse, Wellness, Partnership, Streaking, LG, Communication, NBA, Mental health, Culture, Mental, Duke University, Injury, Electronics, Los Angeles Rams, Head coach, Athlete, Trust, NHL, Basketball, Good, Student, Kate Fitzgerald, NCAA, Nursing

ENGLEWOOD CLIFFS, N.J., May 9, 2024 /PRNewswire/ -- LG Electronics announces the launch of the third season of its podcast, "Transparent Conversations," which brings conversations about mental health directly to college campuses around the country, with live tapings throughout the year at pivotal college sports moments. As a long-standing partner of the National Collegiate Athletic Association (NCAA), LG is committed to this partnership to promote important issues that affect both the physical and mental health of student-athletes. Mental health awareness is a crucial component of LG's commitment to making "Life Good" for all.

Key Points: 
  • Mental health awareness is a crucial component of LG's commitment to making "Life Good" for all.
  • Season Three host, Taylor Rooks, provides a safe space for frank discussions about the mental health challenges facing student-athletes.
  • As a sports journalist, Rooks knows firsthand the critical importance of mental health in not only athletes, but all students.
  • Topics from previous seasons include speaking about student-athlete mental health beyond the college experience and the role of support systems on student-athlete mental health.

Valor Games Southeast Celebrates ‘12 Years Strong’

Retrieved on: 
목요일, 5월 9, 2024
Electronic Design Automation, Data Management, Insurance, Technology, Finance, Biking, Cycling, Professional Services, Philanthropy, Defense, Sports, Foundation, Outdoors, People with Disabilities, Veterans, Networks, Consumer, Disability, Woman, MetLife, Sport, K-Ville, United States Navy, Duke University, Triangle, Multimedia, BIIS

Bridge II Sports (BIIS) is honored to bring the spirit of Valor Games Southeast (VGSE) to the Triangle for the 12th year with the continued support of presenting sponsor MetLife and its employees.

Key Points: 
  • Bridge II Sports (BIIS) is honored to bring the spirit of Valor Games Southeast (VGSE) to the Triangle for the 12th year with the continued support of presenting sponsor MetLife and its employees.
  • View the full release here: https://www.businesswire.com/news/home/20240509981890/en/
    The theme of this year’s Valor Games is “Healing and Recovery Always: Undaunted, Undeterred, Undefined and Unashamed.” Since 2013, VGSE has engaged over 1,000 Veterans with disabilities through the power of adapted sports competition and camaraderie.
  • This year’s games will consist of a three-day event with 11 competition sports at several locations, with closing ceremonies to be held at the MetLife Global Technology Hub in Cary.
  • “We are honored to be able to partner with BIIS to present the VGSE, and to watch these men and women who served our country demonstrate how disability does not define outcomes, opportunities do.”
    For more information on Valor Games Southeast 2024, visit www.bridge2sports.org/ valorgamesse .

Topas Therapeutics Appoints Hugo Fry as CEO

Retrieved on: 
화요일, 5월 7, 2024
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, MSD, University, Commercial, London Business School, Pharmaceutical industry, Duke University, Sanofi Pasteur, Topas, Inflammation, Therapy, Autoimmunity

Topas Therapeutics , a clinical-stage biotech company developing novel antigen-specific immune tolerance therapies to treat autoimmune disorders, announced today the appointment of Hugo Fry as its new Chief Executive Officer.

Key Points: 
  • Topas Therapeutics , a clinical-stage biotech company developing novel antigen-specific immune tolerance therapies to treat autoimmune disorders, announced today the appointment of Hugo Fry as its new Chief Executive Officer.
  • Bringing three decades of experience including senior management and executive roles at both large pharmaceutical and innovative biotechnology companies, Hugo has a significant track record in leading companies from early research and development through product commercialization.
  • “Hugo joins Topas at the right time to provide his broad expertise and strategic direction as we advance our mission of developing novel, disease-modifying treatment options for a range of autoimmune and inflammatory diseases,” commented Erich F. Greiner, Executive Chairman of Topas Therapeutics.
  • “With data from a Phase 2a trial of lead candidate TPM502 in celiac disease expected later this year, we believe Hugo's leadership will drive value for the company and fully leverage the potential of its innovative approach.”
    “Topas is at the forefront of tolerance induction therapy with a cutting-edge nanoparticle technology platform designed to elicit immune tolerization in T-cell-mediated diseases,” said Hugo Fry, CEO of Topas Therapeutics.

Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors

Retrieved on: 
화요일, 5월 7, 2024
Stanford University, University, FGFR, Disorder, Fibroblast growth factor receptor, Hospital, NDA, QED, Achondroplasia, Hematology, Bile duct, Drug, Research and development, MAA, Yale University, RET, Growth, Duke University, Biotechnology, Therapy, Faculty, Osteochondrodysplasia, Harvard Medical School, Multiple sclerosis, Biology, Drug development, Drug discovery, Liver cancer, Bristol Myers Squibb, Massachusetts General Hospital, Puma Biotechnology, Pharmaceutical industry

and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D.

Key Points: 
  • and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D.
  • "Susan and Michael's impressive careers will provide TYRA with valuable guidance as we advance our potential next-generation precision candidates toward people in need.
  • In connection with these appointments, Dr. Chen, who has served as a director since June 2020, has resigned from the TYRA Board.
  • "On behalf of the Board, I want to thank Isan for his many contributions to TYRA.

The Inner Circle Acknowledges, Randi Leigh Sessoms Lassiter as a Distinguished Healthcare Provider

Retrieved on: 
월요일, 5월 6, 2024
APSA, Hospital, American Pediatric Surgical Association, Travel, Trauma, Love, Research, Parent, Photography, Disease, Duke University, ACS, Patient, Bachelor, College, Multimedia, Philosophy, Inner circle, Medical college, Medical degree, Nursing

MINNEAPOLIS, May 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Randi Leigh Sessoms Lassiter is acknowledged as a Distinguished Healthcare Provider for her contributions to the field of Pediatric Surgery.

Key Points: 
  • MINNEAPOLIS, May 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Randi Leigh Sessoms Lassiter is acknowledged as a Distinguished Healthcare Provider for her contributions to the field of Pediatric Surgery.
  • Dr. Lassiter prepared for her vocation attending the College of William and Mary where she earned a Bachelor's degree.
  • She then attended Duke University and received a Medical Degree; completed a residency at the Medical College of Georgia; and a fellowship at Nicholas Children's Hospital.
  • Dr. Lassiter has many highlights in her career and considers becoming board certified in 2023 and finishing her fellowship as her greatest career accomplishment.

Concert Announces Clinical Advisory Board, New Medical Policies

Retrieved on: 
수요일, 5월 1, 2024
Cepheid variable, FDA, Biochemistry, Doctor of Philosophy, Cardiovascular disease, Vanderbilt University Medical Center, Associate, Palmetto, Prevalence, Concert, Global health, Congress, COVID, CRS, Food, Princeton University, Yale University, DRS, Duke University, Microbiology, Infection, Assistant, Molecular biology, Humana, Staphylococcus, Congressional Research Service, MD–PhD, Health, Library, Neuroscience, Research, Personalized medicine, Emory School, Public policy, Immunology, Medicine, Health policy, Maryland School, Government, Division, Rice University, University, Goucher College, Public health, MD, Duke, Staphylococcus aureus, Wake Forest University, Patient, Internal medicine

NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.

Key Points: 
  • The newly formed board will advise Concert on its clinical laboratory content.
  • "Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha.
  • Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name.
  • Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member.

Cloudforce and Microsoft Bring AI to 10th Annual Bitcamp Hackathon at UMD

Retrieved on: 
월요일, 4월 29, 2024
Cloud, Georgetown University, Volunteering, University, Microsoft Surface, Emergency, Education, AI, App Store (iOS/iPadOS), UMD, Francis Scott Key Bridge, Speech, Culture, Duke University, First officer (aviation), Microsoft, Azure, Student

Bitcamp 2024 attracted a record 2,000+ registered hackers to engage in the immersive 36-hour experience.

Key Points: 
  • Bitcamp 2024 attracted a record 2,000+ registered hackers to engage in the immersive 36-hour experience.
  • In addition to its AI focus, Bitcamp offered diverse learning paths across Quantum, Cybersecurity, and App Development.
  • "Our collaboration with Microsoft aims to expose young people to the transformative power of AI and cloud technologies crucial for their career success."
  • Through workshops and interactive sessions—including an innovative prompt-a-thon—Cloudforce and Microsoft team members provided hands-on mentorship to demonstrate industry-leading AI services, including the Azure OpenAI Service and Microsoft Copilot.

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

Retrieved on: 
월요일, 4월 29, 2024
University, Lab, Pancreatic cancer, Survival, Communication, Clinical Laboratory, Research, Duke University

LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.

Key Points: 
  • LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.
  • As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test.
  • Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests.
  • from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis.

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

Retrieved on: 
월요일, 4월 29, 2024
University, Lab, Pancreatic cancer, Survival, Communication, Clinical Laboratory, Research, Duke University

LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.

Key Points: 
  • LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.
  • As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test.
  • Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests.
  • from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis.

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

Retrieved on: 
수요일, 4월 24, 2024
School, OTCQB, Abstract, TSX, MD, Doctor of Philosophy, GBM, ASCO, Duke University, Rated R, Patient, Society, MBA, Annual general meeting, MDNA, University Challenge 2013–14, Pharmaceutical industry

TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) --  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.

Key Points: 
  • TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) --  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.
  • The oral podium presentation will include new clinical data from the ongoing Phase 1/2 ABILITY-1 Study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist, as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®) in patients with advanced or metastatic solid tumors.
  • Details of the podium presentation are as follows:
    Title: “Results from ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-acting IL-2 agonist, in patients with advanced solid tumors”
    Details of the poster presentation are as follows:
    Title: "Phase 2 Study of Bizaxofusp, an IL-4R Targeted Toxin Payload, in Nonresectable Recurrent GBM: Comparison of Overall Survival with Contemporaneous Eligibility-Matched and Propensity Score Balanced External Control Arm"
    Presenter: Dr. John Sampson, MD, PhD, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery, School of Medicine, Duke University, Durham, North Carolina, USA
    The full text of the published abstracts will be available on the 2024 ASCO Annual Meeting website on May 23rd, 2024 at 5:00 PM EDT.